Anavex life sciences announces positive up to 4-years oral blarcamesine results from phase iib/iii open-label extension trial in early alzheimer's disease

Attention-ad trial data through 192 weeks presented at ad/pd tm 2025 conference prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic alzheimer's disease blarcamesine exhibited a favorable safety profile with no treatment-related deaths new york, april 05, 2025 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, today announced that over three years of continuous treatment with blarcamesine (anavex®2-73) demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early alzheimer's disease patients. attention-ad (anavex®2-73-ad-ep-004) trial result was presented at the ad/pdtm 2025 conference.
AVXL Ratings Summary
AVXL Quant Ranking